Company intelligence / Profile preview

DCx Biotherapeutics Corporation

Canada (implied by affiliations with Life Sciences BC)linkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

DCx Biotherapeutics was founded in 2024 with the goal of developing a pipeline of first-in-class precision drug conjugates that are more efficacious and significantly less toxic than traditional antimitotic or topoisomerase inhibiting ADCs. The company’s approach aims to rethink targeted therapies for cancer patients. No clinical data has been reported as of May 2025

Therapeutic areas: Oncology
Modalities: Precision drug conjugates (likely including antibody-drug conjugates and related biologic modalities)
Industry: Biotech

Partnerships

Amplitude Ventures (investor/supporter)recent acquisition of Repare Therapeutics’ assets for synergy in precision oncology

Beyond the preview

Go deeper on DCx Biotherapeutics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCx Biotherapeutics Corporation.

Explore the full profile